Welcome to our dedicated page for AtriCure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AtriCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AtriCure's regulatory disclosures and financial reporting.
AtriCure, Inc. President and CEO Michael H. Carrel reported a new share acquisition through an employee purchase program. On June 30, 2026, he acquired 636 shares of common stock directly at an effective price of $23.78 per share under AtriCure’s 2018 Employee Stock Purchase Plan.
These shares were purchased at 85% of the $27.98 closing price on June 30, 2026, as provided by the plan. After this transaction, Carrel directly holds 779,134 common shares. Additional indirect holdings are reported as shares held by his sibling, parents, and children, for which he disclaims beneficial ownership except for any pecuniary interest.
Chief Scientific Officer Doraiswamy Vinayak acquired additional AtriCure, Inc. common stock through an employee purchase program. On June 30, 2026, he obtained 636 shares of Common Stock pursuant to the company’s 2018 Employee Stock Purchase Plan at $23.78 per share, a price based on 85% of the $27.98 closing price that day. Following this transaction, he directly holds 92,511 common shares, reflecting a small, routine compensation-related acquisition rather than an open-market trade.
AtriCure, Inc. reported that Chief Legal Officer Karl S. Dahlquist acquired 636 shares of common stock on June 30, 2026 through the company’s 2018 Employee Stock Purchase Plan. The shares were acquired at approximately $23.78 per share, based on 85% of the $27.98 closing price on that date, bringing his direct holdings to 96,689 shares.
AtriCure, Inc. Chief Operating Officer Douglas J. Seith acquired 527 shares of common stock through the company’s 2018 Employee Stock Purchase Plan for the period ended June 30, 2026. The shares were purchased at $23.78 each, bringing his direct holdings to 229,867 shares.
AtriCure, Inc. Chief Technical Officer Salvatore Privitera acquired additional company stock through an employee plan. On June 30, 2026, he received 636 shares of common stock, bringing his direct holdings to 158,684 shares. The shares were bought under AtriCure's 2018 Employee Stock Purchase Plan for the period ended June 30, 2026.
According to the plan terms, these shares were purchased at 85% of the June 30, 2026 closing price of $27.98 per share, resulting in an effective purchase price of $23.78 per share. This is a routine compensation-related acquisition rather than an open-market trade.
AtriCure, Inc. director Karen Prange reported an open-market sale of 3,000 shares of common stock on May 20, 2026 at a weighted average price of $28.65 per share. After this transaction, she directly holds 26,373 shares of AtriCure common stock.
The sale was executed in multiple trades within a price range of $28.60 to $28.76 per share, with the reported price reflecting the weighted average sales price.
AtriCure, Inc. director Karen Prange reported an equity compensation grant of common stock. She acquired 6,144 shares of AtriCure common stock at no cash cost as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan, which will vest on the one-year anniversary of the grant date. Following this award, she holds 29,373 common shares directly.
Telman Deborah H reported acquisition or exercise transactions in this Form 4 filing.
AtriCure, Inc. director Deborah H. Telman received a grant of 6,144 shares of Common Stock as a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest on the one-year anniversary of the grant date. Following this award, she holds 28,328 shares of AtriCure common stock directly.
AtriCure, Inc. director Maggie Yuen reported receiving a grant of common stock as equity compensation. She was awarded 6,144 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan.
The award is structured as restricted stock and will vest on the one-year anniversary of the grant date. Following this grant, Yuen directly holds 17,515 shares of AtriCure common stock. This filing reflects a compensation-related acquisition rather than an open-market purchase.
Nachman Shlomo reported acquisition or exercise transactions in this Form 4 filing.
AtriCure director Nachman Shlomo received a grant of 6,144 shares of AtriCure, Inc. common stock as a Restricted Stock Award under the company’s 2023 Stock Incentive Plan. The award was granted at no cash cost and will fully vest on the one-year anniversary of the grant date. Following this equity grant, Shlomo directly owns 24,655 shares of AtriCure common stock.